02 8011 4217, 0416 974 651  info at scenar.com.au

Electric Device For Bisphosphonate-Induced Osteonecrosis

Abstracts of the 2008 International MASCC/ISOO Symposium

Support Care Cancer (2008) 16:619–756  DOI 10.1007/s00520-008-0457-6

Electric Device For Bisphosphonate-Induced Osteonecrosis
Boris Zaidiner1, Ilia Baranovsky2, Darya Leontyeva3, Irene Petrenko2 1Regional Cancer Hospital, Out-patient Care, Rostov-on-Don, Russia, 2Medical Unit, Laboratory of Immunology, Rostov-on-Don, Russia, 3Research Cancer Center, Laboratory of Biophysics, Rostov-on-Don, Russia, 4Medical Unit, Laboratory of Endocrinology, Rostov-on-Don, Russia

Objectives: Osteonecrosis of the jaw (ONJ) is serious adverse event in patients (pts) who administer bisphosphonates for metastatic bone disease. Its management outcome remains poor. To improve results of conventional treatment we’ve used electric therapy device (“SCENAR”, US Patent N 5257623) which was tested in some fields of supportive care. This is attempt to show our experience in SCENAR-technology usage for ONJ.

Methods: In preliminary trial 28 pts with bisphosphonaterelated
ONJ (mean age 59,2 years, range 36–81 years) were enrolled; nosologic forms: breast cancer 9 pts, prostate cancer 7 pts, lung cancer 6 pts, multiple myeloma 3 pts, renal cell cancer 2 pts, far-advanced malignancy without verified primary site – 1 patient. Clinical picture was presented with pain (at rest & jaw movement), swelling, exposed bone; suppuration was noted in 3 pts. Dental surgery prior to bisphosphonate therapy was in almost all pts. After signing the informed consent every patient 15 SCENAR-procedures was performed in addition to conventional supportive care. During these procedures various cutaneous and mucosal areas were treated, their choice was based upon patient’s complaints, their technique was described earlier.

Results: In 17 pts (60,7%) positive results were achieved. They felt better, had partial pain relief (the relief ratings on VAS were significantly improved). In 5 of 19 pts with exposed oral maxillofacial bone the lesions had tendency to heal; in 2 of these 5 pts radiographic changes have become less obvious.

Conclusions: In our study group adding SCENAR to standard therapy appeared to result in more promising outcome then available literature data were presented. Further research is necessary to establish its exact position in multimodal approach for bisphosphonate-related ONJ.